Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted July 10, 2008
Pricey Drugs Put Squeeze on Doctors
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: GLG Member Program Contributor
To enhance health care efficiency, MDs should not have to purchase and stock expensive biotech drugs in their office.  Drugs should be charged to the health plan or PBM and the drugs should arrive at the MDs office labeled for the particular patient
Donald Fleming Posted July 10, 2008
Cancer Care Is getting out of reach
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
The cost of medical care is increasing at an alarming rate The amount of money to support a physician's practice is going down at the same alarming rate especially in oncology
Richard Amerling Posted July 10, 2008
So Much for Health "Insurance"
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: Richard Amerling, Director of Outpatient Dialysis BETH ISRAEL MEDICAL CENTER INC
It's intresting that nowhere in this article was the topic of true insurance for catastrophic illness brought up.  The problem with our current health insurance market is that for most it is pre-paid care, not insurance against a rare, but catastrophic, event. 
Posted July 9, 2008
Costly Cancer Drug Offers Hope, but Also a Dilemma
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Member Program Contributor
Avastin is only one of many new targeted therapies that are expensive.  It was first introduced in colon cancer and has helped to extend the survival of metastatic colon cancer from 3-6 months to 2 years. It has recently been approved for use in lung and breast cancers as well.  It is in these...
Posted July 9, 2008
Pricey Drugs Put Squeeze on Doctors
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: GLG Member Program Contributor
Chemotherapy drugs are so costly that not only are the patients unable to pay co-pays, but oncologists are laying out hundreds of thousands of dollars with only a promise they will be reimbursed.
Posted July 8, 2008
Clash on Preventing Cut to Doctor Payments
Analysis of: Clash on Preventing Cut to Doctor Payments | online.wsj.com
Author: GLG Member Program Contributor
11% drop in physician re-imbursement vs HMO sponsored Medicare "advantage" programs. Who will win out?
Posted July 7, 2008
Costly Cancer Drug Offers Hope, but Also a Dilemma
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Member Program Contributor
Extraordinarily expensive Avastin makes all think twice before using, due to ?? efficacy data as well as questions re: quality of life v survival benefits.
Posted July 7, 2008
Avastin Effecitve in Lung and Breast Cancer But is it Cost Effective?
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Roche has elected not to provide information on the cost effectiveness and clinical effectiveness of Avastin in breast cancer to the medicine advisory board of the British government.  As such, the drug will not be able for first line treatment of these diseases in Britain.
Posted July 3, 2008
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: GLG Member Program Contributor
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
Posted July 3, 2008
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | content.nejm.org
Author: GLG Member Program Contributor
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 708

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics